MPS Long-Term Study
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This study follows people with MPS, a rare genetic condition, to learn more about the disease over time. If you have a confirmed MPS diagnosis, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of MPS (a rare inherited disorder that affects how your body breaks down certain sugars).
- This diagnosis must be based on lab tests showing low levels of a key enzyme, high GAG (a type of sugar) in your urine, or a specific gene change.
- You or your parent/guardian must agree to take part in the study by signing a consent form (if you are a minor or an adult who needs a guardian, they can sign for you).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial enrolls people with mucopolysaccharidosis type VII (MPS VII) to track their health over time. It may help your care team better understand how the condition behaves and how monitoring should be done.
This trial follows people with genetic neurodegenerative (brain-wasting) disorders over time to better understand how the condition changes. The goal is to learn patterns that could help future treatments or care plans.
This study is a registry that collects information from people diagnosed with lysosomal storage diseases. It helps researchers better understand these conditions and support future studies.
This study is for people with MPS II (Hunter syndrome) who have already completed a previous Denali study. It will test a drug called tividenofusp alfa (DNL310) over a longer period to see how safe it is and how well it works.
This program provides access to the medicine Mepsevii for patients who need it but cannot join a clinical trial. It is meant for those with a condition called mucopolysaccharidosis VII (MPS VII), which is a rare genetic disorder that affects the body's ability to break down certain sugars.
This trial tests a gene-transfer treatment (delivered into the spinal fluid) for children with MPS IIIA, a rare genetic condition. It aims to improve or slow down brain and developmental changes caused by a missing enzyme.
Hear when a new Mucopolysaccharidosis I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.